Premium
Two new mutations in the HIF2A gene associated with erythrocytosis
Author(s) -
Percy Melanie J.,
Chung Yu Jin,
Harrison Claire,
Mercieca Jane,
Hoffbrand A. Victor,
Dinardo Carla L.,
Santos Paulo C.J.L.,
Fonseca Guilherme H.H.,
Gualandro Sandra F.M.,
Pereira Alexandre C.,
Lappin Terence R.J.,
McMullin Mary Frances,
Lee Frank S.
Publication year - 2012
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23123
Subject(s) - missense mutation , gene , mutation , erythropoietin , genetics , biology , cancer research , hypoxia inducible factors
Congenital or familial erythrocytosis/polycythemia can have many causes, and an emerging cause is genetic disruption of the oxygen‐sensing pathway that regulates the Erythropoietin ( EPO ) gene. More specifically, recent studies have identified erythrocytosis‐associated mutations in the HIF2A gene, which encodes for Hypoxia Inducible Factor‐2α (HIF‐2α), as well as in two genes that encode for proteins that regulate it, Prolyl Hydroxylase Domain protein 2 (PHD2) and the von Hippel Lindau tumor suppressor protein (VHL). We report here the identification of two new heterozygous HIF2A missense mutations, M535T, and F540L, both associated with erythrocytosis. Met‐535 has previously been identified as a residue mutated in other patients with erythrocytosis; although, the mutation of this particular residue to Thr has not been reported. In contrast, Phe‐540 has not been reported as a residue mutated in erythrocytosis, and we present evidence here that this mutation impairs interaction of HIF‐2α with both VHL and PHD2. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.